Work at Pheon Therapeutics Ltd. has led to the development of new antibody-drug conjugates comprising an antibody or antigen binding fragment targeting CUB domain-containing protein 1 (CDCP1) covalently linked to cytotoxic drug. They are intended for use in the treatment of cancer.